论文部分内容阅读
伊维菌素(Ivermectin)是一种半合成的大环内脂抗菌素,业已证明,它是一种有效的广谱抗家畜寄生虫药物。对人盘尾丝虫感染的临床试验的研究有以下四个阶段。第一阶段:1982年在塞内加尔首先发现伊维菌素5～30μg/kg的单剂量就有杀盘尾丝虫微丝蚴的作用。此后用200μg/kg以内不同剂量治疗一批轻度感染的非洲移民,虽然在某些居民中微丝蚴仍持续发现或重又出现,但结果仍然表明此药有好的效果,在所用剂量的范围内仍属安全和为病人所耐受。重复试验不仅证明此种剂量安全有效,而且证明50μg/kg剂量的效果较差。
Ivermectin, a semi-synthetic macrolide antibiotic, has proven to be an effective broad-spectrum anti-domestic parasitic drug. The clinical trial of Onchocerciasis in humans has the following four stages of research. The first stage: in Senegal in 1982 first found that ivermectin 5 ~ 30μg / kg of a single dose of funicile had Microfilaria filariasis role. Subsequent treatment of a group of mildly infected African migrants with different dosages within 200 μg / kg continued to find or reappear microflora in some residents, but the results still suggest that the drug has a good effect at the doses used The range is still safe and patient tolerant. Repeated trials not only proved that this dose is safe and effective, but also proved less effective at a dose of 50 μg / kg.